PXVX-0317 is under clinical development by Emergent BioSolutions and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect PXVX-0317’s likelihood of approval (LoA) and phase transition for Chikungunya Fever took place on 21 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PXVX-0317 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
PXVX-0317 is under development for the prevention of chikungunya viral infection. The therapeutic candidate is administered through intramuscular route. The vaccine candidate is a virus like particle vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins.
Emergent BioSolutions overview
Emergent BioSolutions (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises, and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent’s pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.
Quick View PXVX-0317 LOA Data
|Highest Development Stage|